Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (1 U54 NS092090-01)
National Institute of Mental Health (MH002961-02)
National Institute of Neurological Disease and Stroke (R01NS105845-01)
Text and Data Mining valid from 2020-02-12
Received: 31 May 2019
Accepted: 23 January 2020
First Online: 12 February 2020
Ethics approval and consent to participate
: Informed consent was obtained for participants, who were enrolled in the Phelan-McDermid Syndrome International Registry (ExternalRef removed).
: All participants signed a release for publication of results.
: AK receives research support from AMO Pharma and consults to Ovid Therapeutics, Takeda, 5 AM Ventures, sema4, and LabCorp. The other authors declare that they have no competing interests.